TEMPLAR NATION

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

19/03/2020: European patent EP 1 694 829 B1, yet another incorrect information on COVID-19

COVID-19, the disease that is reaping thousands of victims and that is affecting the whole world, is now prey to misinterpretations every day.

In recent days, a patent (EP 1 694 829 B1) called “Novel strain of SARS associated Coronavirus and applications thereof” is being distributed via social networks.

According to some, this patent is proof that as early as 2004 some French researchers knew the SARS-CoV-2 virus and the vaccine to defeat it.

Therefore, someone’s plot to deliberately spread the virus would be in place.

Not wanting to discuss who spread the news, we want to focus on the patent trying to give a rational explanation.

In November 2002, an atypical form of very severe pneumonia called “Severe Acute Respiratory Syndrome”, abbreviated as SARS, began to spread in Guangdong province (Canton) in China.

The disease, identified for the first time by the Italian doctor Carlo Urbani (who later died due to it), produced an epidemic over a period of time that went from November 2002 to July 2003, resulting in 8096 cases and 774 deaths in 17 countries (for most in mainland China and Hong Kong), for a final lethality rate of 9.6%.

This disease was caused by a coronavirus (named for its appearance under a microscope), which Chinese scientists tracked down in bats at the end of 2017, with the zibets as intermediary vectors.

The virus responsible for this disease was called SARS-CoV (i.e.SARS associated with Coronavirus), sometimes also written as SARS-CoV-1.

No other SARS cases have been reported anywhere in the world since 2004.

In early 2004, all three researchers from the Institut Pasteur, Centre National de la Recherche Scientifique (CNRS) and Université Paris VII, all from Paris (France), began researching to find an effective vaccine against the SARS-CoV virus.

The research began by analyzing a sample of a patient with SARS, listed at number 031589 and performed at the French hospital in Hanoi (Vietnam).

In December 2004, researchers filed for a patent (EP 1 694 829 B1) of a candidate vaccine against the SARS-CoV virus.

The 2004 patent describes the discovery of the virus and therefore the invention of a vaccination strategy against this virus, not the invention of the virus itself.

Furthermore, only a few laboratories in the world are able to artificially recreate a virus.

Currently, France does not have the necessary equipment to carry out reverse genetics, essential for artificially regenerating a virus.

This technology, created in the 1980s, consists of recovering the virus from a copy of the DNA of the RNA genome.

The new coronavirus, called SARS-CoV-2 and responsible for COVID-19 disease, certainly belongs to the same family, but has little resemblance to SARS-CoV.

SUBSCRIBE

nazione templare

 

REQUEST THE NATIONALITY OF THE
TEMPLAR NATION

Click Here and complete the form  

 

 

Accreditation UUN - Unrepresented United Nations


nazione templare

Click here

Questo sito è stato creato in modo